Table 2.
Change scores for the primary and pre-specified secondary trial outcomes
| Intermittent fasting | Ad libitum control | P-value | |
|---|---|---|---|
| Primary endpoint | |||
| LDL-C (mg/dL) | 0.18 ± 16.7 | 2.48 ± 19.4 | 0.59 |
| Secondary endpoints | |||
| HOMA-IR | −0.75 ± 0.79 | −0.10 ± 1.06 | 0.004a |
| MSS | −0.34 ± 4.72 | 0.31 ± 1.98 | 0.006a |
| BDNF (ng/mL) | 0.59 ± 2.21 | 0.30 ± 1.89 | 0.58 |
| MicroCog GCPi Score | 4.14 ± 8.63 | 1.69 ± 5.51 | 0.17 |
BDNF, brain-derived neurotrophic factor; GCPi, general cognitive proficiency index; HOMA-IR, homeostatic model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; MSS, metabolic syndrome score.
a
Significant at P ≤ 0.01 when corrected for the 4 secondary endpoints and the primary endpoint, as designated a priori at the start of the study.